In this video, health-care analyst David Williamson discusses Valeant's latest acquisition target. Although this is no bite-sized morsel, generic-drug maker Actavis would be a potentially transformative merger of equals.
The deal appears to have hit a snag, and that could be the best outcome for investors in both companies. Valeant probably wouldn't offer Actavis investors much of a premium, and Valeant investors excited about small, accretive deals in the brande-drug space would be in for a rude awakening. Watch and find out why.
What macro trend was Warren Buffett referring to when he said "this is the tapeworm that's eating at American competitiveness"? Find out in our free report: "What's Really Eating at America's Competitiveness." You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.